Clinical Trials Logo

Tumor Lysis Syndrome clinical trials

View clinical trials related to Tumor Lysis Syndrome.

Filter by:

NCT ID: NCT00230217 Completed - Tumors Clinical Trials

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

Start date: March 2004
Phase: Phase 4
Study type: Interventional

This is an open-label, multi-center study with 2 arms. The primary objective is to assess the response to treatment with rasburicase in 2 populations of adult and pediatric patients with lymphoma/leukemia/solid tumor malignancies, those previously treated with a uricolytic agent, and those not previously treated with a uricolytic agent at their first relapse or refractory disease.

NCT ID: NCT00230178 Completed - Cancer Clinical Trials

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Start date: April 2004
Phase: Phase 3
Study type: Interventional

This is a randomized, multi-center, open-label, parallel group study with three arms: - Rasburicase alone - Rasburicase followed by Allopurinol - Allopurinol alone The primary objective is to compare the adequacy of control of plasma uric acid concentration and the safety profile among the three arms.

NCT ID: NCT00186940 Completed - Lymphoma Clinical Trials

Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients

Start date: March 2005
Phase: N/A
Study type: Observational

This is a multi-center trial for rasburicase in children at high risk of tumor lysis syndrome who have a history of asthma/atopy. The main purpose of this study is to establish the safety of this drug in patients with a history of asthma or severe allergies.